Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. (Q46748085)
scientific article
Language:
(P31) (Q13442814)
(P50) (Q37391549)
(Q80438657)
(Q18379159)
(P304) 955-962
(P407) (Q1860)
(P433) 6
(P478) 26
(P577) Friday, February 1, 2008
(P921) (Q134808)
(P1433) (Q400292)
(P1476) "Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group" (language: en)
(P2093) Jon Richards
Eric Whitman
Jose Lutzky
Giorgio Parmiani
Giulio Tosti
John M Kirkwood
Axel Hoos
Lianng Yuh
Renu Gupta
Pramod K Srivastava
C-100-21 Study Group
other details
description scientific article

External Links